Alexion Pharmaceuticals (ALXN) 180.37 $ALXN
CHMP supports updated labeling for Soliris
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 11:55AM CST
ALXN: 180.37 (-2.74)
Pharmacyclics Could Very Well Be The Next Alexion Pharmaceuticals
Investing Healthcare - at Seeking Alpha - Mon Feb 23, 9:52AM CST
JNJ: 102.51 (-0.29), PCYC: 215.93 (-1.89), ALXN: 180.37 (-2.74)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Feb 21, 3:37PM CST
MDLZ: 36.94 (+0.22), DAL: 44.52 (-1.40), KSU: 115.84 (-1.24), AMP: 133.63 (-1.71), LM: 57.27 (-1.03), PCP: 216.30 (-0.80), GOOG: 558.40 (+2.92), HLT: 28.27 (+0.26), DLTR: 79.68 (+0.64), LYB: 85.91 (-0.84), COF: 78.71 (-0.44), FOXA: 35.00 (+0.19), CAR: 60.62 (-0.24), ABBV: 60.50 (-0.02), LOW: 74.09 (-0.01), MA: 90.13 (-1.13), MU: 30.67 (+0.05), ETN: 71.01 (-0.78), FB: 78.97 (-1.44), POT: 35.90 (+0.31), LNG: 80.63 (+2.11), IR: 67.19 (-0.75), NXPI: 84.89 (-0.07), MGM: 21.73 (-0.22), HIG: 40.96 (-0.03), QUNR: 27.19 (-0.65), NFX: 33.03 (-0.57), PXD: 152.52 (-3.51), ABEV: 6.45 (+0.08), ALXN: 180.37 (-2.74), CCI: 86.31 (+0.22), ACT: 291.36 (+1.58), LBTYK: 52.17 (-0.02), C: 52.42 (+0.01), ILMN: 195.46 (-3.00), AON: 100.36 (+0.14), CCE: 46.20 (+0.04), HUM: 164.38 (+1.03), AGN: 232.74 (+0.34), ANTM: 146.45 (-0.27), ACAD: 37.97 (+0.19), LBTYA: 54.06 (-0.40), ALLE: 57.73 (-0.56), GOOGL: 562.63 (+3.34), CTRP: 45.37 (-0.15), BK: 39.14 (-0.30), APD: 156.14 (-0.49), GLNG: 31.02 (-0.35), BRCM: 45.23 (-0.47), BAC: 15.81 (-0.23), NFLX: 474.91 (-8.12), CI: 121.63 (+0.04), HCA: 71.54 (-0.73), BIDU: 203.75 (-2.13), DVA: 74.60 (+0.30), LRCX: 82.46 (-0.92), MHK: 184.35 (-1.80), CP: 187.62 (-0.97), BABA: 85.12 (-0.25)
My Top Biotechnology Stocks For 2015
Stan Stafford - at Seeking Alpha - Thu Feb 19, 8:49AM CST
MDVN: 117.53 (-2.21), CBPO: 76.60 (-0.31), BIIB: 409.59 (-0.51), INSY: 60.06 (-0.65), MYGN: 34.07 (-0.89), PCYC: 215.93 (-1.89), GILD: 103.53 (-0.66), UTHR: 155.05 (-0.53), ALXN: 180.37 (-2.74), LGND: 55.07 (-0.75), ACOR: 33.84 (-1.72), REGN: 413.84 (-6.03), PDLI: 6.98 (+0.03)
Alexion Pharmaceuticals Rises 3.42% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 13, 4:07PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $175.94 to a high of $182.42. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $178.33 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 180.37 (-2.74)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 47.37 (-0.24), ALXN: 180.37 (-2.74), ABBV: 60.50 (-0.02)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 117.53 (-2.21), BLUE: 95.32 (-0.90), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), TGTX: 14.51 (-0.41), TKMR: 18.17 (-0.22), ANAC: 43.50 (-0.60), PBYI: 213.01 (+7.05), REGN: 413.84 (-6.03)
Stock Market News for February 10, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:10AM CST
Markets ended in negative territory for second-consecutive day as intensified concern about Greece’s debt negotiations continued to hurt investor sentiment
HAS: 62.31 (-0.19), ACT: 291.36 (+1.58), MPC: 105.00 (-2.04), HAL: 42.94 (+0.24), ALXN: 180.37 (-2.74), MCD: 98.90 (-0.61), ABBV: 60.50 (-0.02), CVX: 106.68 (-0.38), REGN: 413.84 (-6.03), BHI: 62.51 (+0.01)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 117.53 (-2.21), VRTX: 119.43 (-0.54), ARWR: 7.53 (-0.21), INCY: 85.85 (-1.69), ALXN: 180.37 (-2.74)
New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset Hypophosphatasia Accepted as Late-Breaking Abstracts at the ENDO 2015 Annual Meeting
Business Wire - Mon Feb 09, 5:30AM CST
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new data from a retrospective, multinational natural history study of children with hypophosphatasia (HPP) (symptom onset greater-than or equal to6 months to <18 years) in two separate late-breaking presentations at the Endocrine Society's 97th Annual Meeting and Expo (ENDO). Abstracts summarizing these presentations are published on the ENDO website and can be accessed using the links below. The ENDO annual meeting will be held March 5-8, 2015, in San Diego.
ALXN: 180.37 (-2.74)
Insider Trading Alert - ZEP, ALXN And AHT Traded By Insiders
at The Street - Fri Feb 06, 11:02AM CST
Stocks with insider trader activity include ZEP, ALXN and AHT
AHT: 10.65 (+0.05), ALXN: 180.37 (-2.74), ZEP: 16.63 (-0.22)
Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 54.82 (-0.72), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), BBH: 127.98 (-1.22), IBB: 337.47 (-3.33), AMGN: 157.72 (-1.25)
Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 54.82 (-0.72), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), BBH: 127.98 (-1.22), IBB: 337.47 (-3.33), AMGN: 157.72 (-1.25)
Alexion to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 9:00AM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the 2015 Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 1:50 p.m. ET.
ALXN: 180.37 (-2.74)
Post-Earnings, Alexion Is Financed Heading Into Q1 Regulatory Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 03, 7:06PM CST
ALXN: 180.37 (-2.74)
Alexion Pharmaceuticals (ALXN) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Tue Feb 03, 1:15PM CST
The following Alexion Pharmaceuticals (ALXN) conference call took place on January 29, 2015, 10:00 AM ET. This is a transcript of that earnings call:
ALXN: 180.37 (-2.74)
Biotechs Weigh On Nasdaq; McGraw Hill Rallies
at Investor's Business Daily - Tue Feb 03, 12:30PM CST
Stocks held gains in early afternoon Tuesday, but the Nasdaq lagged. The S&P 500 and the Dow Jones industrial average were up 0.9% and 1.3%, respectively, thanks to strength in energy stocks. The Nasdaq lagged with a 0.4% gain, weighed by weakness in...
SSNC: 60.68 (-0.96), MHFI: 103.10 (-0.39), ALK: 63.65 (-0.33), CELG: 121.53 (-1.82), LUV: 43.24 (-0.84), SAVE: 77.78 (-1.83), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), AAL: 47.90 (-1.45), ADVS: 44.17 (+0.12)
Update: Alexion Q4 Earnings
ONeil Trader - at Seeking Alpha - Tue Feb 03, 9:06AM CST
ALXN: 180.37 (-2.74)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 26.88 (-0.86), ALDX: 10.20 (-0.07), ADHD: 7.53 (-0.07), ALXN: 180.37 (-2.74), ALXA: 2.11 (+0.06)
CHMP supports updated labeling for Soliris
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 11:55AM CST
ALXN: 180.37 (-2.74)
Pharmacyclics Could Very Well Be The Next Alexion Pharmaceuticals
Investing Healthcare - at Seeking Alpha - Mon Feb 23, 9:52AM CST
JNJ: 102.51 (-0.29), PCYC: 215.93 (-1.89), ALXN: 180.37 (-2.74)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Feb 21, 3:37PM CST
MDLZ: 36.94 (+0.22), DAL: 44.52 (-1.40), KSU: 115.84 (-1.24), AMP: 133.63 (-1.71), LM: 57.27 (-1.03), PCP: 216.30 (-0.80), GOOG: 558.40 (+2.92), HLT: 28.27 (+0.26), DLTR: 79.68 (+0.64), LYB: 85.91 (-0.84), COF: 78.71 (-0.44), FOXA: 35.00 (+0.19), CAR: 60.62 (-0.24), ABBV: 60.50 (-0.02), LOW: 74.09 (-0.01), MA: 90.13 (-1.13), MU: 30.67 (+0.05), ETN: 71.01 (-0.78), FB: 78.97 (-1.44), POT: 35.90 (+0.31), LNG: 80.63 (+2.11), IR: 67.19 (-0.75), NXPI: 84.89 (-0.07), MGM: 21.73 (-0.22), HIG: 40.96 (-0.03), QUNR: 27.19 (-0.65), NFX: 33.03 (-0.57), PXD: 152.52 (-3.51), ABEV: 6.45 (+0.08), ALXN: 180.37 (-2.74), CCI: 86.31 (+0.22), ACT: 291.36 (+1.58), LBTYK: 52.17 (-0.02), C: 52.42 (+0.01), ILMN: 195.46 (-3.00), AON: 100.36 (+0.14), CCE: 46.20 (+0.04), HUM: 164.38 (+1.03), AGN: 232.74 (+0.34), ANTM: 146.45 (-0.27), ACAD: 37.97 (+0.19), LBTYA: 54.06 (-0.40), ALLE: 57.73 (-0.56), GOOGL: 562.63 (+3.34), CTRP: 45.37 (-0.15), BK: 39.14 (-0.30), APD: 156.14 (-0.49), GLNG: 31.02 (-0.35), BRCM: 45.23 (-0.47), BAC: 15.81 (-0.23), NFLX: 474.91 (-8.12), CI: 121.63 (+0.04), HCA: 71.54 (-0.73), BIDU: 203.75 (-2.13), DVA: 74.60 (+0.30), LRCX: 82.46 (-0.92), MHK: 184.35 (-1.80), CP: 187.62 (-0.97), BABA: 85.12 (-0.25)
My Top Biotechnology Stocks For 2015
Stan Stafford - at Seeking Alpha - Thu Feb 19, 8:49AM CST
MDVN: 117.53 (-2.21), CBPO: 76.60 (-0.31), BIIB: 409.59 (-0.51), INSY: 60.06 (-0.65), MYGN: 34.07 (-0.89), PCYC: 215.93 (-1.89), GILD: 103.53 (-0.66), UTHR: 155.05 (-0.53), ALXN: 180.37 (-2.74), LGND: 55.07 (-0.75), ACOR: 33.84 (-1.72), REGN: 413.84 (-6.03), PDLI: 6.98 (+0.03)
Alexion Pharmaceuticals Rises 3.42% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 13, 4:07PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $175.94 to a high of $182.42. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $178.33 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 180.37 (-2.74)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 47.37 (-0.24), ALXN: 180.37 (-2.74), ABBV: 60.50 (-0.02)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 117.53 (-2.21), BLUE: 95.32 (-0.90), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), TGTX: 14.51 (-0.41), TKMR: 18.17 (-0.22), ANAC: 43.50 (-0.60), PBYI: 213.01 (+7.05), REGN: 413.84 (-6.03)
Stock Market News for February 10, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:10AM CST
Markets ended in negative territory for second-consecutive day as intensified concern about Greece’s debt negotiations continued to hurt investor sentiment
HAS: 62.31 (-0.19), ACT: 291.36 (+1.58), MPC: 105.00 (-2.04), HAL: 42.94 (+0.24), ALXN: 180.37 (-2.74), MCD: 98.90 (-0.61), ABBV: 60.50 (-0.02), CVX: 106.68 (-0.38), REGN: 413.84 (-6.03), BHI: 62.51 (+0.01)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 117.53 (-2.21), VRTX: 119.43 (-0.54), ARWR: 7.53 (-0.21), INCY: 85.85 (-1.69), ALXN: 180.37 (-2.74)
New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset Hypophosphatasia Accepted as Late-Breaking Abstracts at the ENDO 2015 Annual Meeting
Business Wire - Mon Feb 09, 5:30AM CST
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new data from a retrospective, multinational natural history study of children with hypophosphatasia (HPP) (symptom onset greater-than or equal to6 months to <18 years) in two separate late-breaking presentations at the Endocrine Society's 97th Annual Meeting and Expo (ENDO). Abstracts summarizing these presentations are published on the ENDO website and can be accessed using the links below. The ENDO annual meeting will be held March 5-8, 2015, in San Diego.
ALXN: 180.37 (-2.74)
Insider Trading Alert - ZEP, ALXN And AHT Traded By Insiders
at The Street - Fri Feb 06, 11:02AM CST
Stocks with insider trader activity include ZEP, ALXN and AHT
AHT: 10.65 (+0.05), ALXN: 180.37 (-2.74), ZEP: 16.63 (-0.22)
Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 54.82 (-0.72), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), BBH: 127.98 (-1.22), IBB: 337.47 (-3.33), AMGN: 157.72 (-1.25)
Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 54.82 (-0.72), BIIB: 409.59 (-0.51), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), BBH: 127.98 (-1.22), IBB: 337.47 (-3.33), AMGN: 157.72 (-1.25)
Alexion to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 9:00AM CST
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the 2015 Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 1:50 p.m. ET.
ALXN: 180.37 (-2.74)
Post-Earnings, Alexion Is Financed Heading Into Q1 Regulatory Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 03, 7:06PM CST
ALXN: 180.37 (-2.74)
Alexion Pharmaceuticals (ALXN) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Tue Feb 03, 1:15PM CST
The following Alexion Pharmaceuticals (ALXN) conference call took place on January 29, 2015, 10:00 AM ET. This is a transcript of that earnings call:
ALXN: 180.37 (-2.74)
Biotechs Weigh On Nasdaq; McGraw Hill Rallies
at Investor's Business Daily - Tue Feb 03, 12:30PM CST
Stocks held gains in early afternoon Tuesday, but the Nasdaq lagged. The S&P 500 and the Dow Jones industrial average were up 0.9% and 1.3%, respectively, thanks to strength in energy stocks. The Nasdaq lagged with a 0.4% gain, weighed by weakness in...
SSNC: 60.68 (-0.96), MHFI: 103.10 (-0.39), ALK: 63.65 (-0.33), CELG: 121.53 (-1.82), LUV: 43.24 (-0.84), SAVE: 77.78 (-1.83), GILD: 103.53 (-0.66), ALXN: 180.37 (-2.74), AAL: 47.90 (-1.45), ADVS: 44.17 (+0.12)
Update: Alexion Q4 Earnings
ONeil Trader - at Seeking Alpha - Tue Feb 03, 9:06AM CST
ALXN: 180.37 (-2.74)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 26.88 (-0.86), ALDX: 10.20 (-0.07), ADHD: 7.53 (-0.07), ALXN: 180.37 (-2.74), ALXA: 2.11 (+0.06)
